Sanofi, Boehringer Ingelheim sign definitive agreements for swap
June 27, 2016Research and Development, Sales and Marketing Boehringer Ingelheim, Financial, Sanofi, business swap, merger and acquisition
French drugmaker Sanofi (Euronext: SAN) and German pharma firm Boehringer Ingelheim have signed a definitive agreement for a business swap announced …
Weekly Movers: Lpath, Paratek, Inovio…
June 27, 2016Research and Development, Sales and Marketing
Shares in Lpath (Nasdaq: LPTN) jumped 55% after the company said it has secured a two-year $1.45 million grant by …
Brexit may also create opportunities for UK’s pharmaceutical and medical device industries – report
June 27, 2016Research and Development, Sales and Marketing
Even though UK’s exit from the European Union undoubtedly creates significant issues for the UK pharmaceutical and medical device industries …
Woodley Equipment Company the Specialist Global Provider of Equipment for Clinical Trials exhibits at DIA 2016
June 24, 2016Woodley Equipment Company the Specialist Global Provider of Equipment for Clinical Trials
Astellas UK suspended from ABPI for “deception” and other cultural failings
June 24, 2016Medical Communications, Research and Development, Sales and Marketing ABPI, Astellas, cultural failings
Astellas UK has been suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) for a period …
Nice rejects AstraZeneca’s Tagrisso for lung cancer in preliminary recommendation
June 24, 2016Medical Communications, Research and Development AstraZeneca, CDF, NICE, lung cancer, regulation
UK drugmaker AstraZeneca (LSE: AZN) said the National Institute for Health and Care Excellence (Nice) has rejected Tagrisso (osimertinib) to …
“Immediate challenges” for UK pharma post-Brexit, says ABPI
June 24, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, brexit
The UK life sciences industry has expressed dismay at the result of the EU referendum, but has pledged to work …
FDA approves expanded label for Allergan’s Avycaz
June 24, 2016Medical Communications, Research and Development, Sales and Marketing Allergan, Avycaz, FDA, expanded label
Allergan (NYSE: FDA) has announced that the US Food and Drug Administration (FDA) has approved its supplemental new drug application …
Genmab’s CLL drug gets negative opinion from EMA committee
June 24, 2016Medical Communications, Research and Development, Sales and Marketing Arzerra, CHMP, CLL, EMA, Genmab, blood cancer
Genmab A/S (Nasdaq Copenhagen: GEN) said its drug Arzerra (ofatumumab) received a negative opinion by the Committee for Medicinal Products …
Nice rejects Celgene’s drug to treat blood cancer
June 24, 2016Medical Communications, Research and Development CDF, Celgene, NICE, Vidaza, blood cancer
The National Institute for Health and Care Excellence (Nice) rejected biotech firm Celgene’s (Nasdaq: CELG) Vidaza (azacitidine) to treat a …
Sanofi to add future payments onto Medivation offer, according to reports
June 23, 2016Research and Development, Sales and Marketing Medivation, Sanofi
Sanofi (NYSE: SNY) is considering adding future payments, tied to certain targets, to its proposed $9.3 billion takeover of US …
EU referendum outcome will have major consequences for UK’s pharma sector – GlobalData
June 23, 2016Medical Communications, Sales and Marketing EMA, GlobalData, Pharma sector, brexit, referendum
The outcome of today’s referendum on the UK’s continuing membership of the European Union (EU) will have major consequences for …
Biogen promotes Paul McKenzie to executive vice president
June 23, 2016Biogen (Nasdaq: BIIB) has promoted Paul McKenzie to the role of executive vice president for pharmaceutical operations & technology, effective July …
AstraZeneca set to lose out on $80 million after US turns down flu vaccine
June 23, 2016Sales and Marketing AstraZeneca, CDC, flu, flu vaccine
AstraZeneca has confirmed that its influenza vaccine, FluMist Quadrivalent, will not be used in the US during the 2016-17 flu …
Timely use of Novartis’ Entresto could prevent/delay over 28,000 US deaths a year – study
June 23, 2016Research and Development, Sales and Marketing Entresto, JAMA Cardiology, Novartis, drug trial, research
A timely switch to Novartis’ (VTX: NOVN) heart failure drug Entresto (sacubitril/valsartan) in patients could prevent or delay more than …
New Humira data shows improved quality of life in ulcerative colitis patients
June 23, 2016Research and Development AbbVie, Humira, data, ulcerative colitis
New data on Humira (adalimumab) has been presented at the British Society of Gastroenterology, demonstrating the drug’s efficacy and improvement …
Interview: GSK’s subcutaneous formulation for Benlysta may help cut down hospital visits
June 22, 2016Research and Development Benlysta, EULAR, Interview, Lupus, NICE, autoimmune diseases, drug trial
UK drugmaker GlaxoSmithKine (LSE: GSK) reported positive results for Benlysta following a late-stage study at the annual European Congress of …
Wave Life Sciences granted FDA orphan drug designation for Huntington’s disease drug
June 22, 2016Research and Development FDA, drug, huntington's disease, wave life sciences
Wave Life Sciences (NASDAQ: WVE) has announced that it has received orphan drug designation for the US Food and Drug …
Takeda begins world’s first norovirus vaccine field trial
June 22, 2016Research and Development Takeda, Vaccine, norovirus
Takeda Pharmaceuticals (TSE: 4502) has announced that the first patient has received a dosage of their norovirus vaccine candidate, TAK-214, …
Immunomedics’ chief financial officer resigns, shares fall
June 22, 2016Research and Development, Sales and Marketing Immunomedics, Shares, cfo, stock market
Shares in Immunomedics (Nasdaq: IMMU) fell as much as 11% after the company said its chief financial officer Peter Pfreundschuh …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
